Home › Research › Long-term cohort studies
Age at diabetes diagnosis, genetic susceptibility and dementia risk: a prospective study of 13,126 participants from the UK Biobank
Shiqi Yuan, Qing Liu, Xiaxuan Huang, Zhongliang Xu, Zihong Bai, Liyi Qin, Qiuxiang Shen, Eugene Yee Hing Tang et al.. Medicine Plus, 2025-11-28
Topic: Risk, prevention and care in population studies
Plain-language summary
(1) To investigate the association between age at diabetes diagnosis and the incidence of all-cause dementia (ACD), Alzheimer’s disease (AD), and vascular dementia (VD) in individuals with diabetes. (2) To assess the relationship among age at diabetes diagnosis, dementia polygenic risk score (PRS), APOE ε4 carrier status, and risk of ACD. In a large, population-based cohort with a median follow-up of 13.4 years, participants were stratified by age at diabetes diagnosis ( 60 years). Cox proportional hazards models were used, adjusted for multiple covariates. Genetic risk was assessed using dementia PRS, and APOE ε4 carrier status was considered in the analysis. (1) Individuals diagnosed at ages 50–60 (hazard ratio (HR) = 0.71, 95% CI: 0.55–0.93, P = 0.0117) and > 60 years (HR = 0.59, 95% CI: 0.44–0.79, P 60 years was associated with reduced ACD risk (intermediate PRS: HR = 0.66, 95% CI: 0.44–0.97, P = 0.0035; high PRS: HR = 0.46, 95% CI: 0.26–0.83, P = 0.009). (3) APOE ε4 carrier analysis: in APOE ε4 carriers, diagnosis of diabetes at > 60 years (HR = 0.43, 95% CI: 0.29–0.64, P < 0.001) and at 50–60 years (HR = 0.69, 95% CI: 0.40–0.85, P = 0.005) was associated with a significantly reduced risk of ACD compared to diagnosis at age < 50 years. Later onset of diabetes (age ≥ 50) is associated with a lower risk of ACD, particularly among individuals with higher genetic susceptibility to dementia, including APOE ε4 carriers. These findings highlight the importance of early diabetes management and targeted lifestyle interventions in high-risk populations to potentially reduce dementia risk.
What this study adds
Evidence grade: Moderate
In this UK Biobank cohort, people diagnosed with diabetes at age 50 or older had a lower risk of all-cause dementia than those diagnosed before age 50, including among APOE ε4 carriers. Reported effect size: HR = 0.59; HR = 0.66; HR = 0.46.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Yuan, S., Liu, Q., Huang, X., Xu, Z., Bai, Z., Qin, L., et al. (2025). Age at diabetes diagnosis, genetic susceptibility and dementia risk: a prospective study of 13,126 participants from the UK Biobank. Medicine Plus. https://doi.org/10.1016/j.medp.2025.100111
Vancouver
Yuan S, Liu Q, Huang X, Xu Z, Bai Z, Qin L, et al. Age at diabetes diagnosis, genetic susceptibility and dementia risk: a prospective study of 13,126 participants from the UK Biobank. Medicine Plus. 2025. doi:10.1016/j.medp.2025.100111.
BibTeX
@article{yuan2025-5709812f,
author = {Yuan, Shiqi and Liu, Qing and Huang, Xiaxuan and Xu, Zhongliang and Bai, Zihong and Qin, Liyi and Shen, Qiuxiang and Tang, Eugene Yee Hing and others},
title = {{Age at diabetes diagnosis, genetic susceptibility and dementia risk: a prospective study of 13,126 participants from the UK Biobank}},
journal = {Medicine Plus},
year = {2025},
doi = {10.1016/j.medp.2025.100111},
url = {https://doi.org/10.1016/j.medp.2025.100111}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- (1) Individuals diagnosed at ages 50–60 (hazard ratio (HR) = 0.71, 95% CI: 0.55–0.93, P = 0.0117) and > 60 years (HR = 0.59, 95% CI: 0.44–0.79, P < 0.001) had significantly lower ACD risk compared to those diagnosed at age < 50 years.
- (3) APOE ε4 carrier analysis: in APOE ε4 carriers, diagnosis of diabetes at > 60 years (HR = 0.43, 95% CI: 0.29–0.64, P < 0.001) and at 50–60 years (HR = 0.69, 95% CI: 0.40–0.85, P = 0.005) was associated with a significantly reduced risk of ACD compared to diagnosis at age < 50 years.
- Later onset of diabetes (age ≥ 50) is associated with a lower risk of ACD, particularly among individuals with higher genetic susceptibility to dementia, including APOE ε4 carriers.
- These findings highlight the importance of early diabetes management and targeted lifestyle interventions in high-risk populations to potentially reduce dementia risk.
Why it matters
In this UK Biobank cohort, people diagnosed with diabetes at age 50 or older had a lower risk of all-cause dementia than those diagnosed before age 50, including among APOE ε4 carriers. The study reports an association between age at diabetes diagnosis and dementia risk, not a treatment or prevention strategy.
Study details
- Effect sizeHR = 0.59; HR = 0.66; HR = 0.46
- Evidence strengthModerate
How this study scored 37/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Medicine Plus) |
| Journal's citation record | 0 / 4 | Medicine Plus: journal h-index 12 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Jun Xu: h-index 18 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Capital Medical University: institution h-index 643 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Long-term cohort studies from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.